Bristol Myers touts long-term efficacy of recently acquired Karuna drug
06 Apr 2024
AcquisitionClinical Result
Fresh off closing its $14 billion acquisition of Karuna Therapeutics a few weeks ago, Bristol Myers Squibb is presenting long-term data for its new subsidiary’s promising schizophrenia drug, known as KarXT.
Bristol Myers said KarXT’s efficacy was maintained through one year in an open-label extension, presenting the data Saturday at the Schizophrenia International Research Society congress. Additionally, more than 75% of patients who continued taking the drug for a year achieved a “clinically meaningful” result, BMS senior VP of global drug development Roland Chen told Endpoints News.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.